2023-08-082023-08-082016-09-09Kalyoncu, U. vd. (2017). ''The psoriatic arthritis registry of Turkey: Results of a multicentre registry on 1081 patients''. Rheumatology, 56(2), 279-284.1462-03241462-0332https://doi.org/10.1093/rheumatology/kew375https://academic.oup.com/rheumatology/article/56/2/279/2447889http://hdl.handle.net/11452/33393Çalışmada 48 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.Objective. The aim was to assess the characteristics of PsA, find out how well the disease is controlled in real life, demonstrate the treatments and identify the unmet needs. Methods. The PsA registry of Turkey is a multicentre Web-based registry established in 2014 and including 32 rheumatology centres. Detailed data regarding demographics for skin and joint disease, disease activity assessments and treatment choices were collected. Results. One thousand and eighty-one patients (64.7% women) with a mean (S.D.) PsA duration of 5.8 (6.7) years were enrolled. The most frequent type of PsA was polyarticular [437 (40.5%)], followed by oligoarticular [407 (37.7%)] and axial disease [372 (34.4%)]. The mean (S.D.) swollen and tender joint counts were 1.7 (3) and 3.6 (4.8), respectively. Of these patients, 38.6% were on conventional synthetic DMARD monotherapy, 7.1% were on anti-TNF monotherapy, and 22.5% were using anti-TNF plus conventional synthetic DMARD combinations. According to DAS28, 86 (12.4%) patients had high and 105 (15.2%) had moderate disease activity. Low disease activity was achieved in 317 (45.7%) patients, and 185 (26.7%) were in remission. Minimal disease activity data could be calculated in 247 patients, 105 of whom (42.5%) had minimal disease activity. The major differences among sexes were that women were older and had less frequent axial disease, more fatigue, higher HAQ scores and less remission. Conclusion. The PsA registry of Turkey had similarities with previously published registries, supporting its external validity. The finding that women had more fatigue and worse functioning as well as the high percentage of active disease state highlight the unmet need in treatment of PsA.eninfo:eu-repo/semantics/openAccessPsoriatic arthritisRegistryDisease activityInflammatory back-painAnkylosing-spondylitisClinical historyDisease-activityHealth-careClassificationcriteriaCriteriaSpondyloarthritisRecommendationsPrevalenceActivities of daily livingAge distributionAntirheumatic agentsArthritis, psoriaticFatigueFemaleHealth services needs and demandHumansMaleMiddle agedPatient reported outcome measuresRegistriesRemission inductionSeverity of Illness IndexSex distributionTumor necrosis factor-alphaTurkeyAdultBook0003970506000182-s2.0-8503980958027928656227794533RheumatologyComplex; Viscometry; Schiff BasesAdalimumabDisease modifying antirheumatic drugEtanerceptGlucocorticoidGolimumabInfliximabMethotrexateTumor necrosis factor inhibitorAntirheumatic agentTumor necrosis factorAdultArthralgiaArticleAxial diseaseCombination drug therapyDAS28Disease activityDisease controlDisease durationFatigueFemaleHealth assessment questionnaireHealth care needHumanJoint swellingMajor clinical studyMaleMiddle agedMonotherapyOligoarticular psoriatic arthritisPatient-reported outcomePhysicianPolyarticular psoriatic arthritisPriority journalPsoriatic arthritisRegisterRemissionSex differenceTurkey (republic)Visual analog scaleAge distributionAntagonists and inhibitorsArthritisPsoriaticClinical trialComplicationDaily life activityFatigueHealth serviceMulticenter studyPathophysiologySeverity of illness indexSex ratioTurkey